<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802995</url>
  </required_header>
  <id_info>
    <org_study_id>BDU005</org_study_id>
    <nct_id>NCT02802995</nct_id>
  </id_info>
  <brief_title>Safety And Efficacy Of Topical Platelet Rich Plasma And Thrombin Coagulum</brief_title>
  <official_title>Safety And Efficacy Of Topical Platelet Rich Plasma And Thrombin Coagulum In The Treatment Of Recalcitrant Venous Stasis Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Witwatersrand, South Africa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to

        -  To evaluate the safety and tolerability of Platelet Rich plasma(PRP)/Thrombin mixture in
           treating chronic venous ulcers

        -  To evaluate efficacy of PRP/Thrombin mixture in treating chronic venous ulcers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study rationale

      In normal wound healing, platelets activate macrophages to produce endogenous platelet
      derived growth factor (PDGF) and other growth factors which are responsible for would
      healing. In chronic wounds, macrophage activation is suppressed which leads to an
      inappropriate growth factor response causing failure of positive autocrine feedback loop
      which normally controls the healing process. The regular application of exogenous PRP and
      Thrombin, to chronic wounds, restores the autocrine feedback loop of tissue repair which
      appears to accelerate the normal cascade of tissue repair

      Objectives

        -  To evaluate the safety and tolerability of PRP/Thrombin mixture in treating chronic
           venous ulcers

        -  To evaluate efficacy of PRP/Thrombin mixture in treating chronic venous ulcers
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Resource issue
  </why_stopped>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of the wound treated with the PRP/thrombin mixture</measure>
    <time_frame>12 weeks</time_frame>
    <description>Size of the wound will be measured at the end of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and type adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse events will reported at the start and throughout the treatment period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Stasis Ulcer</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving the study drug which is PRP/thrombin mixture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects receiving the standard of care for chronic venous wounds</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRP/thrombin mixture</intervention_name>
    <description>Mixture of platelet rich plasma and thrombin applied topically on the wound surface</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>thrombostim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to give written informed consent

          -  Age 18 years to 75 years.

          -  Both males and females.

          -  Ankle branchial index of 0.8 or above.

        Exclusion Criteria:

          -  Diabetics will be excluded as the Ankle Branchial Index (ABI) result is considered an
             unreliable due the possible presence of arteriosclerotic plaques (lead pipe rigidity).

          -  Patients who have participated in experimental drug studies within 30 days of entering
             this study.

          -  receiving chemotherapy or radiotherapy for malignant diseases or any other indication

          -  Patients taking corticosteroids or other immunosuppressive medications

          -  Clinically malnourished patients or those with recent (last 4 weeks without treatment)
             serum albumin of less than 30g/l.

          -  Patients with current or past history of acute deep vein thrombosis.

          -  Patients with current signs and/or symptoms of cardiac, renal or hepatic failure.
             Renal failure defines as Creatinine

          -  Patients with signs and/or symptoms of peripheral neuropathy.

          -  Patients with signs and/or symptoms of ATROPHIE BLANCHE or other conditions associated
             with non-chronic venous insufficiency ulceration of the lower leg.

          -  Patients with signs and/or symptoms of immunocompromized sates or recent (last 4 weeks
             ) T cell subset (CD4) count of less than 200 cells / ml.

          -  Patients showing clinical signs and/or symptoms of anaemia or current or recent(last 4
             weeks without treatment) haemoglobin level of less than 8g/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnny Mahlangu, MBBCH, MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of the Witwatersrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charlotte Maxeke Johannesburg Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Callam MJ, Ruckley CV, Harper DR, Dale JJ. Chronic ulceration of the leg: extent of the problem and provision of care. Br Med J (Clin Res Ed). 1985 Jun 22;290(6485):1855-6.</citation>
    <PMID>3924283</PMID>
  </reference>
  <reference>
    <citation>Dolynchuk K, Keast D, Campbell K, Houghton P, Orsted H, Sibbald G, Atkinson A. Best practices for the prevention and treatment of pressure ulcers. Ostomy Wound Manage. 2000 Nov;46(11):38-52; quiz 53-4. Review.</citation>
    <PMID>11889736</PMID>
  </reference>
  <reference>
    <citation>Franz RC. Platelet concentrate-thrombin coagulum: a new biological dressing for the promotion of wound healing. S Afr Med J. 1987 Dec 5;72(11):810-1. Erratum in: S Afr Med J 1988 Jan 23;73(2):137.</citation>
    <PMID>3686285</PMID>
  </reference>
  <reference>
    <citation>Franz RW, Shah KJ, Halaharvi D, Franz ET, Hartman JF, Wright ML. A 5-year review of management of lower extremity arterial injuries at an urban level I trauma center. J Vasc Surg. 2011 Jun;53(6):1604-10. doi: 10.1016/j.jvs.2011.01.052. Epub 2011 Apr 8.</citation>
    <PMID>21477966</PMID>
  </reference>
  <reference>
    <citation>Hammermeister KE, Johnson R, Marshall G, Grover FL. Continuous assessment and improvement in quality of care. A model from the Department of Veterans Affairs Cardiac Surgery. Ann Surg. 1994 Mar;219(3):281-90.</citation>
    <PMID>8147609</PMID>
  </reference>
  <reference>
    <citation>Hess CT. Pressure ulcer evidence-based treatment pathway integrated with evidence-based decisions: part 3. Adv Skin Wound Care. 2013 Sep;26(9):432. doi: 10.1097/01.ASW.0000434207.28117.5d.</citation>
    <PMID>23958876</PMID>
  </reference>
  <reference>
    <citation>Phillips LG, Mann R, Heggers JP, Linares HA, Robson MC. In vivo ovine flap model to evaluate surgical infection and tissue necrosis. J Surg Res. 1994 Jan;56(1):1-4.</citation>
    <PMID>8277759</PMID>
  </reference>
  <reference>
    <citation>Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem. 1991 Apr;45(4):319-26. Review.</citation>
    <PMID>2045423</PMID>
  </reference>
  <reference>
    <citation>Pierce GF, Brown D, Mustoe TA. Quantitative analysis of inflammatory cell influx, procollagen type I synthesis, and collagen cross-linking in incisional wounds: influence of PDGF-BB and TGF-beta 1 therapy. J Lab Clin Med. 1991 May;117(5):373-82.</citation>
    <PMID>2019792</PMID>
  </reference>
  <reference>
    <citation>Roe DF, Gibbins BL, Ladizinsky DA. Topical dissolved oxygen penetrates skin: model and method. J Surg Res. 2010 Mar;159(1):e29-36. doi: 10.1016/j.jss.2009.10.039. Epub 2009 Nov 21.</citation>
    <PMID>20097370</PMID>
  </reference>
  <reference>
    <citation>Steed DL, Ricotta JJ, Prendergast JJ, Kaplan RJ, Webster MW, McGill JB, Schwartz SL. Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic acid (RGD) peptide matrix. RGD Study Group. Diabetes Care. 1995 Jan;18(1):39-46.</citation>
    <PMID>7698046</PMID>
  </reference>
  <reference>
    <citation>Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998 May;21(5):822-7.</citation>
    <PMID>9589248</PMID>
  </reference>
  <reference>
    <citation>Wilkins RG, Unverdorben M. Wound cleaning and wound healing: a concise review. Adv Skin Wound Care. 2013 Apr;26(4):160-3. doi: 10.1097/01.ASW.0000428861.26671.41. Review.</citation>
    <PMID>23507692</PMID>
  </reference>
  <results_reference>
    <citation>Atri SC, Misra J, Bisht D, Misra K. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery. 1990 Sep;108(3):508-12.</citation>
    <PMID>2396195</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Witwatersrand, South Africa</investigator_affiliation>
    <investigator_full_name>Johnny Mahlangu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

